A Phase 1 Open-label, Single-dose Study Designed to Assess the Mass Balance Recovery and Metabolite Profile and to Identify Metabolite Structures for [14C]-CORT125281 in Healthy Subjects
Latest Information Update: 25 Mar 2019
At a glance
- Drugs Exicorilant (Primary)
- Indications Prostate cancer
- Focus Pharmacokinetics
- Sponsors Corcept Therapeutics
- 25 Mar 2019 New trial record